Effect of irinotecan combined with cisplatin on serum levels of Bcl-2 and MACC1 protein in patients with cervical cancer
- VernacularTitle:伊立替康联合顺铂对宫颈癌患者血清Bcl－2及MACC1蛋白的影响
- Author:
Chaojun YUAN
;
Bing JIANG
- Publication Type:Journal Article
- Keywords:
irinotecan;
cisplatin;
cervical cancer;
Bcl-2;
MACC1
- From:
Chinese Journal of Biochemical Pharmaceutics
2015;(12):94-96
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate effect of irinotecan combined with cisplatin on level of Bcl-2 and MACC1 protein in serum in patients with cervical cancer.Methods 92 cases of patients with cervical cancer surgery from department of gynaecology and obstetrics,the third People’s hospital of Nanchang were randomly divided into control group and treatment group.Control group was treated with paclitaxel therapy chemotherapy, treatment group were treated with irinotecan combined with cisplatin.Bcl-2 and MACC1 protein in serum were compared before and after the treatment. Results The level of Bcl-2 and MACC1 in both groups were not statistically significant pre-treatment;After treatment, the levels of Bcl-2 and MACC1protein in serum were decreased (P<0.05).Compared with control group post-treatment, the level of Bcl-2 and MACC1 protein in serum were lower in treatment group (P<0.05).During follow-up, death cases of treatment group and control group were 5 cases and 6 cases respectively, the survival rate of 89.13% and 86.96% respectively within the past six months(χ2 =0.103,P>0.05).Death cases of treatment group and control group were 4 cases and 12 cases respectively. the survival rate of 91.30% and 73.91% respectively within one year (χ2 =4.84, P <0.05 ) Conclusion Irinotecan combined with cisplatin in the treatment of cervical cancer in one year survival rate is higher, which may be related to the decrease of serum levels of Bcl-2 and MACC1 protein content.
